T. Rowe Price Associates’s Axonics, Inc. Common Stock AXNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-31,286
| Closed | -$2.18M | – | 3083 |
|
|
2024
Q3 | $2.18M | Buy |
31,286
+403
| +1% | +$27.6K | ﹤0.01% | 1597 |
|
|
2024
Q2 | $2.08M | Buy |
30,883
+1,986
| +7% | +$134K | ﹤0.01% | 1536 |
|
|
2024
Q1 | $1.99M | Buy |
28,897
+1,828
| +7% | +$123K | ﹤0.01% | 1566 |
|
|
2023
Q4 | $1.69M | Buy |
27,069
+1,416
| +6% | +$79.2K | ﹤0.01% | 1625 |
|
|
2023
Q3 | $1.44M | Buy |
25,653
+1,166
| +5% | +$65.6K | ﹤0.01% | 1621 |
|
|
2023
Q2 | $1.24M | Buy |
24,487
+1,804
| +8% | +$96K | ﹤0.01% | 1693 |
|
|
2023
Q1 | $1.24M | Buy |
22,683
+756
| +3% | +$44.2K | ﹤0.01% | 1675 |
|
|
2022
Q4 | $1.37M | Buy |
21,927
+676
| +3% | +$44.9K | ﹤0.01% | 1616 |
|
|
2022
Q3 | $1.5M | Buy |
21,251
+10,385
| +96% | +$716K | ﹤0.01% | 1566 |
|
|
2022
Q2 | $616K | Buy |
10,866
+326
| +3% | +$17.9K | ﹤0.01% | 2136 |
|
|
2022
Q1 | $660K | Sell |
10,540
-19,087
| -64% | -$1.03M | ﹤0.01% | 2218 |
|
|
2021
Q4 | $1.66M | Sell |
29,627
-398,493
| -93% | -$24.4M | ﹤0.01% | 1790 |
|
|
2021
Q3 | $27.9M | Sell |
428,120
-3,233
| -0.7% | -$221K | ﹤0.01% | 1200 |
|
|
2021
Q2 | $27.4M | Sell |
431,353
-29,111
| -6% | -$1.72M | ﹤0.01% | 1224 |
|
|
2021
Q1 | $27.6M | Sell |
460,464
-2,268
| -0.5% | -$123K | ﹤0.01% | 1192 |
|
|
2020
Q4 | $23.1M | Sell |
462,732
-312
| -0.1% | -$14.6K | ﹤0.01% | 1189 |
|
|
2020
Q3 | $23.6M | Buy |
463,044
+933
| +0.2% | +$38.9K | ﹤0.01% | 1110 |
|
|
2020
Q2 | $16.2M | Buy |
+462,111
| New | +$15.9M | ﹤0.01% | 1192 |
|
Other funds holding AXNX
T. Rowe Price Associates's AXNX Position: Q4 2024 in Review
T. Rowe Price Associates sold out of Axonics, Inc. Common Stock (AXNX) in Q4 2024, closing a stake of 31,286 shares — an estimated $2.18M sold.
T. Rowe Price Associates first reported a position in AXNX in Q2 2020 and held it in 18 quarters. The position peaked at $27.9M in Q3 2021. 2 funds tracked by Wall St. Rank hold AXNX as of Q4 2024.
- T. Rowe Price Associates reported no remaining Axonics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- T. Rowe Price Associates sold 31,286 Axonics, Inc. Common Stock shares in Q4 2024, an estimated $2.18M.
- T. Rowe Price Associates first reported a position in Axonics, Inc. Common Stock in Q2 2020 and held it in 18 quarters.
- T. Rowe Price Associates's Axonics, Inc. Common Stock position peaked at $27.9M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Axonics, Inc. Common Stock as of Q4 2024.
Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.